About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.
This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of Zevalin, OPAXIO,
pixantrone and brostallicin include risks associated with preclinical and
clinical developments in the biopharmaceutical industry in general and with
Zevalin, OPAXIO, pixantrone and brostallicin in particular including,
without limitation, the ability of the Company to continue to raise capital
to fund its ongoing operations, or the potential failure of Zevalin to be
approved by the FDA for first-line treatment of non-Hodgkin's lymphoma, the
failure of OPAXIO, pixantrone or brostallicin to prove safe and effective
for their intended uses, a determination by the EMEA that OPAXIO should not
be approved for sale in Europe, other determinations by regulatory, patent
and administrative governmental authorities, competitive factors,
technological developments, costs of developing, producing and selling
Zevalin, OPAXIO, pixantrone and brostallicin, the risk that Novartis may
not elect to participate in the dev
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved